Tag Archives: Rintatolimod

Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection

Posted on 01/13/2021 by wames

Clinical Trial Arena: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection, 7 January 2021   AIM ImmunoTech has dosed its first Covid-19 ‘long hauler’ patient in the active AMP-511 Expanded Access Program (EAP) with the Ampligen (rintatolimod) … Continue reading →

Posted in News | Tagged , , , , , , , | Comments Off on Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection

Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for ME/CFS

Posted on 11/04/2020 by wames

Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, by David R Strayer, Diane Young, William M Mitchell in  PLoS ONE 15(10): e0240403, Oct 29 2020 [doi.org/10.1371/journal.pone.0240403]   Research … Continue reading →

Posted in News | Tagged , , , , , , , | Comments Off on Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for ME/CFS

Endocrine immune regulation in… women with CFS

Posted on 04/24/2019 by wames

Leveraging prior knowledge of endocrine immune regulation in the therapeutically relevant phenotyping of women with Chronic Fatigue Syndrome, by Matthew C Morris, Katherine Cooney, Hooman Sedghamiz, Maria Abreu, Fanny Collado, Elizabeth G Balbin, Travis JA Craddock, Nancy G Klimas, Gordon … Continue reading →

Posted in News | Tagged , , , , , , , , , , , , , , | Comments Off on Endocrine immune regulation in… women with CFS